Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials
- PMID: 30421439
- PMCID: PMC6336516
- DOI: 10.1111/cen.13901
Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials
Abstract
Objective: Studies of dehydroepiandrosterone (DHEA) therapy in older adults suggest sex-specific effects on bone mineral density (BMD) and body composition, but the ability of a single study to reach this conclusion was limited. We evaluated the effects of DHEA on sex hormones, BMD, fat mass and fat-free mass in older women and men enrolled in four similar clinical trials.
Design: Pooled analyses of data from four double-blinded, randomized controlled trials.
Participants: Women (n = 295) and men (n = 290) aged 55 years or older who took DHEA or placebo tablet daily for 12 months.
Measurements: Twelve-month changes in BMD, fat mass, fat-free mass and serum DHEA sulphate (DHEAS), (17)estradiol, testosterone and insulin-like growth factor-1 (IGF-1).
Results: Women on DHEA had increases (mean ± SD; all P < 0.001 vs placebo) in DHEAS (231 ± 164 µg/dL), testosterone (18.6 ± 20.9 µg/dL), (17)estradiol (8.7 ± 11.0 pg/mL) and IGF-1 (25.1 ± 52.3 ng/mL), and men had increases in DHEAS (269.0 ± 177 µg/dL; P < 0.01), (17)estradiol (4.8 ± 12.2 pg/m; P < 0.01) and IGF-1 (6.3 ± 41.4 ng/mL; P < 0.05). Women on DHEA had increases in lumbar spine (1.0% ± 3.4%) and trochanter (0.5% ± 3.8%) BMD and maintained total hip BMD (0.0% ± 2.8%); men had no BMD benefit and a decrease in fat mass (-0.4 ± 2.6 kg; all P < 0.01 vs placebo).
Conclusions: Dehydroepiandrosterone therapy may be an effective approach for preserving bone and muscle mass in women. Key questions are (a) the extent to which longer duration DHEA can attenuate the loss of bone and muscle in women, and (b) whether DHEA has a more favourable benefit-to-risk profile for women than oestrogen therapy.
Keywords: ageing; bone density; dehydroepiandrosterone; fat mass; fat-free mass; prohormone; sex differences.
© 2018 John Wiley & Sons Ltd.
Figures
Similar articles
-
Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial.J Clin Endocrinol Metab. 2006 Aug;91(8):2986-93. doi: 10.1210/jc.2005-2484. Epub 2006 May 30. J Clin Endocrinol Metab. 2006. PMID: 16735495 Clinical Trial.
-
Effects of DHEA replacement on bone mineral density and body composition in elderly women and men.Clin Endocrinol (Oxf). 2000 Nov;53(5):561-8. doi: 10.1046/j.1365-2265.2000.01131.x. Clin Endocrinol (Oxf). 2000. PMID: 11106916 Clinical Trial.
-
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32. doi: 10.1046/j.1365-2265.1998.00507.x. Clin Endocrinol (Oxf). 1998. PMID: 9876338 Clinical Trial.
-
[Hormones and osteoporosis update. Adrenal androgen and bone].Clin Calcium. 2009 Jul;19(7):963-9. Clin Calcium. 2009. PMID: 19567992 Review. Japanese.
-
Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.Drugs Aging. 2003;20(13):949-67. doi: 10.2165/00002512-200320130-00001. Drugs Aging. 2003. PMID: 14561100 Review.
Cited by
-
Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application.Pharmaceuticals (Basel). 2024 Sep 9;17(9):1186. doi: 10.3390/ph17091186. Pharmaceuticals (Basel). 2024. PMID: 39338348 Free PMC article. Review.
-
Association of Hormonal Exposures With Grip Strength in Women >45 Years: Data From the CONSTANCES Cohort Study.J Endocr Soc. 2024 Sep 9;8(10):bvae150. doi: 10.1210/jendso/bvae150. eCollection 2024 Aug 27. J Endocr Soc. 2024. PMID: 39290336 Free PMC article.
-
Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes.Pituitary. 2024 May 6. doi: 10.1007/s11102-024-01391-2. Online ahead of print. Pituitary. 2024. PMID: 38709467 Review.
-
The Current Landscape of Pharmacotherapies for Sarcopenia.Drugs Aging. 2024 Feb;41(2):83-112. doi: 10.1007/s40266-023-01093-7. Epub 2024 Feb 5. Drugs Aging. 2024. PMID: 38315328
-
Steroid hormone levels and bone mineral density in women over 65 years of age.Sci Rep. 2023 Mar 25;13(1):4925. doi: 10.1038/s41598-023-32100-x. Sci Rep. 2023. PMID: 36966199 Free PMC article.
References
-
- Dhatariya KK, Nair KS. Dehydroepiandrosterone: is there a role for replacement? Mayo Clinic proceedings. 2003;78(10):1257–1273. - PubMed
-
- Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. The Journal of clinical endocrinology and metabolism. 1984;59(3):551–555. - PubMed
-
- Labrie F DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97–148. - PubMed
-
- Labrie F, Belanger A, Luu-The V, et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids. 1998;63(5–6):322–328. - PubMed
-
- Lamberts SW. The endocrinology of gonadal involution: menopause and andropause. Ann Endocrinol (Paris). 2003;64(2):77–81. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
